Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL

PURPOSE: In the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2), the pan–erythroblastic oncogene B inhibitor neratinib was available to all hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) subtypes and gr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JCO Precis Oncol
Autori principali: Wulfkuhle, Julia D., Yau, Christina, Wolf, Denise M., Vis, Daniel J., Gallagher, Rosa I., Brown-Swigart, Lamorna, Hirst, Gillian, Voest, Emile E., DeMichele, Angela, Hylton, Nola, Symmans, Fraser, Yee, Douglas, Esserman, Laura, Berry, Donald, Liu, Minetta, Park, John W., Wessels, Lodewyk F.A., van’t Veer, Laura, Petricoin, Emanuel F.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2018
Soggetti:
Original Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446527/
https://ncbi.nlm.nih.gov/pubmed/32914002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00024
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi